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© 201? Japanese Society of Tropical Medicine Abstract: Dengue virus (DENV) is a leading cause of morbidity and mortality in most tropical and subtropical
areas of the world. Dengue virus infection induces specific CD4+CD8– and CD8+CD4– T cells in humans. In
primary infection, T-cell responses to DENV are serotype cross-reactive, but the highest response is to the serotype
that caused the infection. The epitopes recognized by DENV-specific T cells are located in most of the structural
and non-structural proteins, but NS3 is the protein that is most dominantly recognized. In patients with dengue
hemorrhagic fever (DHF) caused by secondary DENV infection, T cells are highly activated in vivo. These highly
activated T cells are DENV-specific and oligoclonal. Multiple kinds of lymphokines are produced by the activated
T cells, and it has been hypothesized that these lymphokines are responsible for induction of plasma leakage, one
of the most characteristic features of DHF. Thus, T-cells play important roles in the pathogenesis of DHF and in
the recovery from DENV infection.
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1. INTRODUCTION
Dengue fever (DF)/dengue hemorrhagic fever (DHF)
is one of the most important infectious diseases in tropical
and subtropical areas of the world. The areas where DF/DHF
is a serious health concern have been expanding, and the
number of DHF patients has been increasing. The immune
responses to DENV have been analyzed in humans. The
antibody responses are well known and the roles of specific
antibodies in the prevention of DENV infection and in the
pathogenesis of DHF have been established. On the other
hand, T-cell responses to DENV is not as well understood as
that of antibodies.
2. DENGUE VIRUS (DENV)
DENV belongs to the family Flaviviridae, the genus
Flavivirus. The genome of dengue virus is a single, plus-
stranded RNA nearly 11 Kb in length. The open reading
frame codes three structural proteins (capsid (C) protein,
preM protein, and envelope (E) protein) and seven non-
structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b
and NS5). Dengue virion has a spherical shape and mea-
sures 40–50 nm in diameter. The envelope is a lipid bilayer
containing two envelope-associated proteins: the E and M
proteins.
DENV is transmitted to humans by infected mosquitoes,
mainly Aedes aegypti and Aedes albopictus. Humans are
natural hosts of DENV, and DENV is maintained between
mosquitoes and humans in nature. There are four serotypes:
DENV types 1, 2, 3 and 4. Although DENV types 1, 2, 3
and 4 are referred to as serotypes, it is generally accepted
that the four serotypes are different albeit antigenically
related species.
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3. DENGUE FEVER (DF) AND DENGUE 
HEMORRHAGIC FEVER (DHF); TWO CLINICAL 
MANIFESTATIONS OF DENGUE VIRUS INFECTION
Dengue virus infection can be asymptomatic or cause
two forms of illness, DF and DHF, although the majority of
DENV infections are asymptomatic. New diagnostic names
have recently been proposed [1], but the terms DF and DHF
are still widely used.
DF is a self-limiting febrile illness. After an incubation
period of 2–7 days, a sudden onset of fever occurs. The
fever is usually accompanied by retro-orbital or frontal
headache. Myalgia and bone pain occur soon after the onset
of fever. A transient macular rash that blanches under pres-
sure, nausea, vomiting, lymphadenopathy and taste aberra-
tions can develop. These symptoms are accompanied by
leucopenia and variable degrees of thrombocytopenia. One
to two days after defervescence, a generalized morbilliform
maculopapular rash appears. The rash spares palms and
soles. Patients usually recover from the symptoms without
complications about a week after the onset of disease.
Some patients infected with dengue virus demonstrate
plasma leakage into interstitial spaces, thrombocytopenia and
also hemorrhagic manifestation. This severe life-threatening
syndrome is called DHF. The incubation period of DHF is
similar to that of DF. Illness starts with fever, malaise,
vomiting, headache, anorexia, and cough. Rapid clinical
deterioration and collapse follow after 2–5 days. In the
second phase, the patients demonstrate cold clammy ex-
tremities, warm trunk, flushed face, restlessness, irritability,
middle gastric pain, and may progress to a rapid weak pulse,
hypotention and narrow pulse pressure. The crisis lasts for
24–36 hours, and the patients may require fluid therapy,
but usually recover rapidly once convalescence starts. The
hematological manifestations include an increase in
hematocrit, thrombocytopenia, a prolonged bleeding time,
and an increased prothrombin time. The temperature returns
to normal when capillary leakage occurs. The occurrence of
capillary leakage differentiates DHF from DF. When plasma
leakage is so profound that shock occurs, it is also referred
to as dengue shock syndrome (DSS).
4. T-CELL RESPONSES TO DENV
T-cells are known to play an important role in recovery
from virus infections in general. Analysis of T-cell responses
to DENV is essential to understand the mechanism of
recovery from DENV infections and also the pathogenesis
of DHF. There are not very satisfactory animal models to
analyze T-cell responses to dengue virus and pathogenesis
of DHF, although many groups have attempted to do so [2].
Analysis of human peripheral blood mononuclear cells
(PBMC) is still the best way to elucidate the DENV-specific
T-cell responses.
4-1. Analysis of memory T-cells
T-cell responses to DENV have been analyzed mainly
using memory T-cells in PBMCs. DENV-specific memory
CD4+CD8– T-cells and CD4–CD8+ T cells were detected
in PBMCs from human subjects after natural infection with
dengue virus, or after immunization with experimental,
live-attenuated dengue vaccines.
4-2. Analysis of DENV-specific CD4+ memory T-cells
Specific CD4+CD8– memory T-cells induced by
primary DENV infection were serotype-cross-reactive in
bulk culture analysis, but the highest response was to the
same serotype that caused the infection [3]. In some sub-
jects, however, CD4+ T-cell memory responses after primary
infection were serotype-specific [4]. The presence of
serotype-cross-reactive and serotype-specific CD4+ T-cells
was also demonstrated in precursor frequency assays [5].
In PBMC from DENV-1-immunizued individuals, the fre-
quency of DENV-1 responsive T-cells was nearly 10 times
higher than the frequency of other three serotypes [5].
DENV-specific CD4+ T-cell clones were established
and analyzed for serotype specificities and functions. Most of
the T-cell clones demonstrated specific cytotoxic activities.
Consistent with the results of bulk culture analyses, DENV-
specific CD4+ T-cell clones established from respective
subjects have at least two types of serotype specificities:
dengue serotype-specific and serotype-cross-reactive [6, 7].
The patterns of serotype cross-reactivities, and the propor-
tion of serotype-specific and cross-reactive clones varied
among individuals.
4-3. Analyses of DENV-specific CD8+ memory T-cells
DENV-specific CD8+CD4– memory T-cells induced
by primary DENV infections were serotype cross-reactive
in bulk culture analysis, and the highest response was to the
same serotype that caused the primary infection [8]. DENV-
specific CD8+ T-cell clones were established. The clones
also contained serotype-specific and serotype cross-reactive
clones [9]. Thus, similar to CD4+ T-cell responses, DENV
infection with one serotype of DENV induces both serotype-
specific and serotype cross-reactive CD8+ memory T-cells.
5. PROTEINS RECOGNIZED BY DENV-SPECIFIC 
T-CELLS
Proteins recognized by DENV-specific T-cells were
determined in bulk culture and T-cell clonal analyses. In47 I. Kurane et al.
these analyses, the non-structural proteins NS3 and NS1,2a
were determined to be the proteins mainly recognized by
both CD4+T cells and CD8+T cells [10–13]. However,
other proteins such as C, E and NS4b also contained T cell
epitopes [14–16]. The recognition pattern of the proteins
differs according to the type of HLA.
6. ACTIVATION OF T CELLS IN VIVO IN PATIENTS 
WITH DF/DHF
Activation of DENV-specific T cells in vivo has been
analyzed using PBMC samples obtained in early stages of
DF and DHF by some groups. Green et al. reported that
absolute counts of CD4+ T-cells, CD8+ T-cells, NK cells,
and  γδT-cells were decreased in children with DHF
compared to those with DF early in the course of illness.
The percentage of cells expressing CD69, an activation
marker, was more increased in CD8+ T-cell and NK cell
populations in children who developed DHF than in those
with DF [17]. Mongkolsapaya et al. reported that many
CD8+ T-cells possessed an activation phenotype and were
undergoing programmed cell death [18]. These studies
provided direct evidence of T-cell activation in vivo in the
acute phase of DENV infections.
Activation of T-cells has also been suggested by
increased levels of lymphokines in serum or plasma samples
from patients with DF/DHF. It has been reported that levels
of IL-2, IFNγ and other lymphokines are highly elevated in
patients with DHF compared to those with DF, and healthy
subjects [19]. Serum levels of soluble tumor necrosis factor
receptors (sTNFRs), soluble CD8 and soluble IL-2 receptor
were higher in children who developed DHF than in those
with DF or non-dengue febrile illness [20]. These studies
indicated that T-cells are highly activated in patients with
DF and DHF, and the levels of T cell activation are higher in
patients with DHF than in those with DF. The results also
suggested that activation of CD8+ T-cells is more profound
than that of CD4+ T-cells. The results suggesting massive T-
cell activation in DHF are summarized in Table 1.
7. DETERMINATION OF THE CLONALITY OF 
T-CELLS ACTIVATED IN VIVO IN PATIENTS 
WITH DF/DHF
As stated above, T-cells are highly activated in patients
with DF and DHF, and there is a positive relationship
between the levels of T-cell activation and severity of
dengue illness [21]. One of the important questions is: Are
the majority of activated T-cells DENV-specific, or are
most of the activated T cells non-specific for DENV and
activated as bystanders? This question was addressed by
analyzing T-cell receptors.
The usage of T-cell receptor α-chain variable region
(TCRAV) and β-chain variable region (TCRBV) repertoires
was analyzed in patients with DF or DHF. This analysis
can determine whether T-cell activation in the patients is
antigen-specific. If common antigens are responsible for
proliferation of the T-cells, complementarity-determining
region 3 (CDR3) diversity should be constrained, and
homologous CDR3 sequences might be found in the T cells
[22, 23]. We then determined the nucleotide sequences of
CDR3 of TCR α-chain and β-chain gene from the T-cells.
The delta score was used as an indicator to evaluate the
extent of skew of TCR repertoires [24]. The delta score
indicates the sum of absolute differences between the
frequencies of respective V segments.
Peripheral blood mononuclear cells (PBMC) were
collected from patients with DF or DHF on study days –4,
–2, 2 and 180, where day 0 is defined as the day of defer-
vescence. These donors developed dengue illness after
secondary infections. TCR analysis was performed by micro-
plate hybridization assay, size spectratyping and sequencing
of CDR3 region. We determined whether T-cells are oligo-
clonally expanded in dengue patients, and whether there is a
unique T-cell receptor usage in patients with DHF or DF.
The patterns of T-cell receptor usage changed in
individuals during the course of illness. The pattern of TCR
usage on day 180 was considered the control for each of the
patients. Representative data for TCR VB usage in PBMC
from a donor is shown in Figure 1. The percentages of T-
cells with VB051 and VB091 increased significantly. The
TCRs that demonstrated an increase in percentage differ
from donor to donor. In order to estimate the levels of skew
in TCR usage, delta scores were calculated (Figure 2). The
delta scores changed between acute and convalescent stages,
suggesting the skew in TCR usage. There was a positive
relationship between delta scores and the severity of dengue
illness; the levels of skew of TCR usage were greater in
Table 1. Characteristics of T-cell responses in patients with DF
and DHF.
1. T-cell responses to DENV in primary infection are serotype
cross-reactive, but the highest response is to the serotype
that caused the primary infection. Most of the memory T-cells
after secondary infection are serotype cross-reactive.
2. Massive T-cell activation in DHF.
* High percentage of CD69+ T-cells.
* The levels of T-cell activation: Higher in CD8+ T-cell 
poputation than in CD4+ T-cell population.
* High levels of lymphokines: IL-2, IL-6, IL-8, IL-10, 
TNF-α, IFN-γ
* High levels of cellular proteins: sIL-2R, sCD4, sCD8, 
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patients with DHF grades 3 and 4 (Figure 3). Clonality of
activated T-cells was then evaluated by size spectratyping
of the CDR3 of TCRs that demonstrated increased usage.
The CDR3 of these TCRs showed only a few peaks,
suggesting that T-cells with these TCRs proliferated in an
oligoclonal fashion. The nucleotide sequences of the CDR3
regions of these TCRs showed that a high percentage of the
sequenced CDR3 clones had identical amino acid sequences
(Table 2). These results are consistent with those of the
spectratyping analyses and confirmed that activation of T-
cells is oligoclonal in some of the DHF patients (Figure 4).
The results suggest that the majority of T-cells highly
activated in vivo are DENV-specific in patients with DHF.
Fig. 1.  T-cell receptor usage in PBMCs collected from a patient with DHF.
TCR VB usage in PBMC from a patient with DHF. PBMCs were collected on days –4, –2, 2 and 180, where day 0 is defined
as the day of defervescence.
Fig. 2.  Delta scores of TCR AV and BV.
Delta scores were compared between acute and conva-
lescent stages. P < 0.01 between acute and convalescent
stages in TCR AV and BV.
Fig. 3.  Relationship between TCR delta scores and the severi-
ty of dengue illness.
There was a positive relationship between delta scores
and severity of dengue illness in TCR BV usage.49 I. Kurane et al.
8. ROLE OF T-CELLS IN THE PATHOGENESIS OF DHF
The role of the activated T-cells in the pathogenesis of
DHF has been hypothesized [25]. A series of studies have
suggested that plasma leakage, which differentiates DHF
from DF, is caused by malfunction of vascular endothelial
cells induced by cytokines or chemical mediators rather
than by destruction of the small vessels [26, 27]. Plasma
levels of various lymphokines are significantly higher in
DHF than in DF. The lymphokines elevated in patients with
Table 2. Alignment of amino acid sequences of CDR3 regions in TCRs that demonstrated increased levels of usage
Patient Fever Days Occurrence AV/BV segment
Amino acid sequences in CDR3 region
AJ/BJ segment
AV/BV seq. N (N-D-N) AJ/BJ seq.
K94-017 0 2/7 AV1S4 YFCAVS P NRDDKIIFG AJ30
K94-029 1 3/8 AV1S4 YFCAVS AS NSGGSNYKLTFG AJ53
K94-029 1 5/7 AV21S1 YFCAAS F SGGYQKVTFG AJ13
K94-041 −4 & −2 6/7 AV31S1 YLCA AEY TGGFKTIFG AJ9
K94-007 1 3/11 AV14S1 YFCAYRS GG YKLSFG AJ20
C94-138 0 5/7 AV20S1 YYCLVGD D DYKLSFG AJ20
K94-041 −4 6/6 BV9S1 YFCASS FS NEQFFG BJ2S1
−2 3/5 BV9S1 YFCASSQ DRD SGANVLTFG BJ2S6
K94-004 −1 8/11 BV6S5 YLCASS RGG EQYFG BJ2S7
C94-081 −2 2/7 BV8S1 YFCASS YG NEQFFG BJ2S1
Fig. 4.  Size spectratyping of CDR3 of selected TCRs in PBMCs obtained from patients with DF and DHF.
PBMCs were collected on days –4, –2, 2 and 180, where day 0 is defined as the day of defervescence.50 Tropical Medicine and Health Vol.39 No.4 Supplement, 2011
DHF include TNF-α, IL-2, IL-6, IL-8, IL-10, IL-12 and
IFN-γ. However, it is not clearly understood how these
lymphokines cause malfunction of vascular endothelial
cells and lead to plasma leakage.
Some of the cytokines, i.e. IFN-γ, IL-2 and TNF-α
were mainly produced by DENV-specific T-cells upon
activation [28]. It is likely, therefore, that activated specific
T-cells are responsible for increased levels of cytokines that
play a key role in the pathogenesis of DHF. Consistent with
the assumption, there was a correlation between the levels
T-cell activation and dengue disease severity. It should,
however, be understood that these activated T-cells may
also contribute to the recovery from DENV infection, as has
been reported in other virus infections.
9. CONCLUSIONS
New findings regarding T-cell responses to DENV
have been accumulating. However, a complete understanding
of the T-cell activation in patients with DF and DHF and the
roles of activated T-cells in recovery and in the pathogenesis
of DHF remains a challenge. A better understanding of T-cell
responses as well as function and role in DENV infection will
facilitate the development of dengue vaccines, new treat-
ment programs and measures to prevent DENV infection.
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